What one share of ProKidney holds
We are a late-clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advanced chronic kidney disease (“CKD”) and diabetes.
ProKidney’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.01 |
|---|---|
| Profit | −$0.55 |
| Capex (buildings and equipment) | $0.12 |
| Free cash flow | −$1.05 |
| Cash and investments | $0.40 |
| Book value | −$4.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.00 | −$0.57 | $0.55 | −$2.00 | — | −$17.73 |
| 2024 | $0.00 | −$0.62 | $0.30 | −$1.58 | — | −$10.08 |
| 2025 | $0.01 | −$0.52 | $0.11 | −$1.02 | — | −$7.62 |
Common questions about ProKidney
How much does one share of ProKidney earn?
Over the last 12 months, ProKidney lost $0.55 for each share on $0.01 of sales.
Does ProKidney pay a dividend?
ProKidney didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is ProKidney’s book value per share?
ProKidney’s book value is negative (−$4.66 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of ProKidney have?
Each share of ProKidney has $0.40 of cash and investments, as of June 30, 2026.
What is ProKidney’s free cash flow per share?
−$1.05 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.